600276 Jiangsu Hengrui Pharmaceuticals Co.,Ltd.
Not Yet Opened 07-01 09:30:00
38.46
+0.00
0.00%
High
0.00
Low
0.00
Vol
0.00
Open
0.00
D1 Closing
38.46
Amplitude
0.00%
Mkt Cap
245.34B
Tradable Cap
245.34B
Total Shares
6.38B
T/O
0.00
T/O Rate
0.00%
Tradable Shares
6.38B
P/B
5.86
ROE
--
EPS
0.00
52wk High
--
52wk Low
--
P/E
--
Dividend
--
Div.Yield
--
ROA
--
Time
5D
D
W
M
News
New Post(s)
Profile
Hengrui Pharmaceuticals Gets Nod to Trial Vitiligo Drug
MT Newswires Live · 05-30
Hengrui Pharmaceuticals Gets Nod to Trial Vitiligo Drug
Hengrui Pharma Gets China Drug Registration Certificate for Ovarian, Fallopian Tube Cancer Drugs
MT Newswires Live · 05-22
Hengrui Pharma Gets China Drug Registration Certificate for Ovarian, Fallopian Tube Cancer Drugs
Jiangsu Hengrui Medicine Earnings Growth May Continue to Accelerate -- Market Talk
Dow Jones · 03-15
Jiangsu Hengrui Medicine Earnings Growth May Continue to Accelerate -- Market Talk
Load more
Introduction
Company Name.
江苏恒瑞医药股份有限公司
Industry:
医药制造业
Listing Date:
2000-10-18
Main Business:
江苏恒瑞医药股份有限公司主营业务涉及药品研发、生产和销售,主要产品是艾瑞昔布片、甲磺酸阿帕替尼片、硫培非格司亭注射液、马来酸吡咯替尼片、卡瑞利珠单抗、甲苯磺酸瑞马唑仑、氟唑帕利胶囊、海曲泊帕乙醇胺片、羟乙磺酸达尔西利片、脯氨酸恒格列净片、瑞维鲁胺片、阿得贝利单抗注射液、磷酸瑞格列汀片、富马酸泰吉利定注射液、林普利塞片、奥特康唑胶囊。报告期内,公司荣获中国医药质量管理协会颁发的“首批无菌药品质量保障企业”荣誉称号、江苏省医药质量管理协会颁发的“江苏省医药行业优秀质量管理企业”荣誉称号;公司“雏鹰QC小组”、“远志QC小组”被评为江苏省医药行业质量管理(QC)发表交流优秀小组。
Issue price:
11.98
{"stockData":{"symbol":"600276","market":"SH","secType":"STK","nameCN":"Jiangsu Hengrui Pharmaceuticals Co.,Ltd.","latestPrice":38.46,"timestamp":1719795867000,"preClose":38.46,"halted":0,"volume":0,"delay":0,"changeRate":0,"floatShares":6379000000,"shares":6379000000,"eps":0.6949,"marketStatus":"Not Yet Opened","change":0,"latestTime":"07-01 09:30:00","open":0,"high":0,"low":0,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":0.6949,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1719797400000},"marketStatusCode":0,"adr":0,"adjPreClose":38.46,"symbolType":"stock","openAndCloseTimeList":[[1719797400000,1719804600000],[1719810000000,1719817200000]],"highLimit":42.31,"lowLimit":34.61,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":6379002274,"isCdr":false,"pbRate":5.86,"roa":"--","peRate":55.346093,"roe":"3.33%","epsLYR":0.68,"committee":0,"marketValue":245336000000,"turnoverRate":0,"status":2,"nextConnectDate":"Northbound have stopped. The next trading day is UTC+8 2024-07-02.","floatMarketCap":245336000000},"requestUrl":"/m/hq/s/600276","defaultTab":"news","newsList":[{"id":"2439657920","title":"Hengrui Pharmaceuticals Gets Nod to Trial Vitiligo Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2439657920","media":"MT Newswires Live","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2439657920?lang=en_us&edition=fundamental","pubTime":"2024-05-30 11:47","pubTimestamp":1717040838,"startTime":"0","endTime":"0","summary":"Jiangsu Hengrui Pharmaceuticals will conduct clinical trials on the SHR0302 alkaline gel as a treatment for vitiligo after obtaining the approval of Chinese drug regulator National Medical Products Administration, according to the company's filing on the Shanghai Stock Exchange. About 855.3 million yuan has been invested into the research and development of SHR0302-related drugs, which were approved as treatment for ankylosing spondylitis, atopic dermatitis and rheumatoid arthritis, the pharmaceutical company said in its Wednesday filing. Price : 42.89, Change: -0.13, Percent Change: -0.30%","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1328615791.USD","LU0405327148.USD","BK0028","LU1064130708.USD","LU2148510915.USD","BK0183","LU1064131003.USD","BK0188","600276","BK0012","BK0239","LU0405327494.USD","BK0196","BK0060"],"gpt_icon":0},{"id":"2437254019","title":"Hengrui Pharma Gets China Drug Registration Certificate for Ovarian, Fallopian Tube Cancer Drugs","url":"https://stock-news.laohu8.com/highlight/detail?id=2437254019","media":"MT Newswires Live","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2437254019?lang=en_us&edition=fundamental","pubTime":"2024-05-22 17:46","pubTimestamp":1716371160,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_live","symbols":["600276"],"gpt_icon":0},{"id":"2419916365","title":"Jiangsu Hengrui Medicine Earnings Growth May Continue to Accelerate -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2419916365","media":"Dow Jones","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2419916365?lang=en_us&edition=fundamental","pubTime":"2024-03-15 13:49","pubTimestamp":1710481740,"startTime":"0","endTime":"0","summary":"0549 GMT - Jiangsu Hengrui Medicine is likely to report strong earnings growth in 4Q 2023 and into 2024, helped by revenue recognition and sales pick up, Nomura analysts Jialin Zhang and Yi Xiang say in a research note. They expect Hengrui's 4Q sales to have grown 14.3% on a low base and continued growth of innovative drugs. Its 4Q gross profit margin likely improved by 0.3 percentage points to 84.1% on economies of scale and an increase in the proportion of high-margin innovative drugs, the analysts say. They raise Hengrui's 2023 and 2024 net profit forecasts by 3.2% and 11.6%, respectively. They increase the stock's target to CNY51.12 from CNY49.24 and maintain a neutral call. Shares last at CNY46.79. ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["600276","AAQC"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2000-10-18","address":"江苏省连云港市连云区经济技术开发区黄河路38号","stockEarnings":[{"period":"1week","weight":-0.0395},{"period":"1month","weight":-0.106},{"period":"3month","weight":-0.1634},{"period":"6month","weight":-0.1497},{"period":"1year","weight":-0.1826},{"period":"ytd","weight":-0.1497}],"companyName":"江苏恒瑞医药股份有限公司","boardCode":"AI0027","perCapita":"14482股","boardName":"医药制造业","registeredCapital":"637900万元","compareEarnings":[{"period":"1week","weight":-0.0103},{"period":"1month","weight":-0.0462},{"period":"3month","weight":-0.0243},{"period":"6month","weight":-0.0025},{"period":"1year","weight":-0.0676},{"period":"ytd","weight":-0.0025}],"survey":" 江苏恒瑞医药股份有限公司主营业务涉及药品研发、生产和销售,主要产品是艾瑞昔布片、甲磺酸阿帕替尼片、硫培非格司亭注射液、马来酸吡咯替尼片、卡瑞利珠单抗、甲苯磺酸瑞马唑仑、氟唑帕利胶囊、海曲泊帕乙醇胺片、羟乙磺酸达尔西利片、脯氨酸恒格列净片、瑞维鲁胺片、阿得贝利单抗注射液、磷酸瑞格列汀片、富马酸泰吉利定注射液、林普利塞片、奥特康唑胶囊。报告期内,公司荣获中国医药质量管理协会颁发的“首批无菌药品质量保障企业”荣誉称号、江苏省医药质量管理协会颁发的“江苏省医药行业优秀质量管理企业”荣誉称号;公司“雏鹰QC小组”、“远志QC小组”被评为江苏省医药行业质量管理(QC)发表交流优秀小组。","serverTime":1719795884765,"listedPrice":11.98,"stockholders":"440465人(较上一季度减少5.31%)","compareStock":{"symbol":"000001.SH","name":"SSE Comp"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.24.2","shortVersion":"4.24.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Jiangsu Hengrui Pharmaceuticals Co.,Ltd.(600276),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Jiangsu Hengrui Pharmaceuticals Co.,Ltd.(600276) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Jiangsu Hengrui Pharmaceuticals Co.,Ltd.,600276,Jiangsu Hengrui Pharmaceuticals Co.,Ltd.股票,Jiangsu Hengrui Pharmaceuticals Co.,Ltd.股票老虎,Jiangsu Hengrui Pharmaceuticals Co.,Ltd.股票老虎国际,Jiangsu Hengrui Pharmaceuticals Co.,Ltd.行情,Jiangsu Hengrui Pharmaceuticals Co.,Ltd.股票行情,Jiangsu Hengrui Pharmaceuticals Co.,Ltd.股价,Jiangsu Hengrui Pharmaceuticals Co.,Ltd.股市,Jiangsu Hengrui Pharmaceuticals Co.,Ltd.股票价格,Jiangsu Hengrui Pharmaceuticals Co.,Ltd.股票交易,Jiangsu Hengrui Pharmaceuticals Co.,Ltd.股票购买,Jiangsu Hengrui Pharmaceuticals Co.,Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Jiangsu Hengrui Pharmaceuticals Co.,Ltd.(600276),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Jiangsu Hengrui Pharmaceuticals Co.,Ltd.(600276) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}